Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

INmune Bio Q3 Adj. EPS $(0.24) Beats $(0.33) Estimate

Author: Benzinga Newsdesk | October 30, 2025 03:14pm
INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.33) by 26.15 percent. This is a 60 percent increase over losses of $(0.60) per share from the same period last year.

Posted In: INMB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist